AHA Urges HHS to Stop Drug Companies’ Refusal to Provide Required 340b Discounts

AHA follows up on our previous correspondence on the serious situation Eli Lilly, AstraZeneca and Sanofi are creating for the nation’s most vulnerable communities by refusing to comply with the requirements of the 340B program to sell to contract pharmacies at the discounts required by section 340B of the Public Health Service Act.

Related Resources

Letter/Comment
Public
The AHA on Friday sent a letter to the Health Resources and Services Administration’s Office of Pharmacy Affairs urging the agency to order drug manufacturers…
Letter/Comment
Public
In a letter to Senator Lamar Alexander and Representative Greg Walden, AHA expresses strong support for the 340B Drug Pricing Program.
Action Alert
Member
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary…
Action Alert
Member
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary…
Fact Sheets
Public
The Issue: Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at…
Letter/Comment
Public
AHA comments on the Centers for Medicare…